The combination of Ceftazidime + Avibactam (Torgena®) is classified as a high-cost medication by the institution. In 2025, the maximum sale price to the government of Paraná, according to regulation by the Drug Market Regulation Chamber (CMED), was the unit value of R842. 04. Dose unitization consists of preparing and labeling medications based on the prescription, ready for administration. In the economic context, rational use of medicines aims to reduce costs for patients and society without compromising treatment quality. Given the above, the study aims to characterize the use of Ceftazidime + Avibactam (Torgena®) in a university, public, reference hospital, and to measure the effects of unitization of prescribed doses. The project was approved by the institution’s Research Ethics Committee (CAAE: 86159818. 6. 0000. 5231). This is a descriptive cross-sectional study that analyzed prescriptions of the antimicrobial Ceftazidime + Avibactam (Torgena®) for adult patients admitted to intensive care units and wards of the hospital. The study period comprised all prescriptions issued between January 1 and June 10, 2025. Data were extracted from the hospital systems Esthos and Medview, based on prescriptions and patient medical records. The analysis also included medication consumption, assessing the total number of vials used, consumption per patient/day, and savings generated by dose fractionation (1. 25 g and 0. 94 g), which are adjusted according to the patient’s renal function and prepared according to an in-house manual. Ninety-two patients were identified, with a mean age of 54 years. Of these, 46. 73% (43 patients) received their doses (1. 25 g and 0. 940 g) through the Unit Dose sector, generating savings of 24 vials, equivalent to R20, 208. 96. Consumption of Ceftazidime + Avibactam (Torgena®) varied from 11. 4 vials/average per day to 3. 795 mg/day in cases of fractionated doses. This work demonstrates that providing fractionated doses of Ceftazidime + Avibactam (Torgena®) through the Unit Dose sector not only generates savings, but also promotes greater safety and quality in treatment, aligning with the principles of rational use of medicines.
Prado et al. (Sun,) studied this question.